Although anti-IL-5 treatment and anti-IL-4/IL-13 treatment are clinically available for treating eosinophil-dominant severe asthma, recent research has been mainly focused on molecules that are more upstream, such as thymic stromal lymphopoietin. Here, TSLP is linked to asthma.